Company: HURA
Filing Date: 2025-05-23
Form Type: 424B3
Source: 0001193125-25-125499
Chunk: 53

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-23
Form: 424B3
Chunk 53
---
 applicable Optionholder 
 Treatment Agreement and, upon such exercise, will be entitled to receive the Merger Consideration;                                                                     |

| • |     | each                                                                                                           
 Out-of-the-Money Company Stock Option held by a Person will be canceled and extinguished for no consideration; |

| • |     | the Pre-2023 Company Warrants will terminate upon their terms if such Pre-2023 Company Warrants are not previously exercised (if the Pre-2023 Company Warrants are exercised prior to the Effective Time, as a holder of shares of Kineta Common 
 Stock, the holder of such former Pre-2023 Company Warrants will be entitled to receive the Merger Consideration);                                                                                                                                |

| • |     | the 2023 Company Warrants will be entitled to the benefits as set forth in the applicable Warrantholder Treatment 
 Agreement.                                                                                                        |

On March 7, 2025, Kineta entered into a securities exchange agreement (the “Exchange Agreement”) with an existing investor and holder of some of the 2023 Company Warrants (the “Holder”) pursuant to which Kineta agreed to issue an aggregate of 1,880,342 shares of Kineta Common Stock consisting of (i) an aggregate of 1,225,323 shares of Kineta Common Stock and (ii) a pre-funded warrant to purchase up to an aggregate of 655,019 shares of Kineta Common Stock, in exchange for certain outstanding 2023 Company Warrants (the “Prior Warrants”) held by the Holder to purchase up to 2,315,387 shares of Kineta Common Stock with exercise prices ranging from $3.25 to $4.08 (the “Exchange”). Kineta has cancelled the Prior Warrants reacquired in the Exchange and such Prior Warrants will not be reissued. In addition, pursuant to the Exchange Agreement, in connection with the transactions contemplated by the Merger Agreement, the Holder agreed to (i) appear in person or online (for a virtual meeting) or by proxy at the Kineta special meeting and (ii) vote (or cause to be voted) the shares of Kineta Common Stock held by the Holder in favor of the approval of the Merger Agreement Proposal, the Compensation Proposal and the Kineta Adjournment Proposal. After giving effect to the Exchange, some of the 2023 Company Warrants remain outstanding. Asset Sales (see page 255) Partnered Programs Asset Sale Kineta has also entered into the HCRX Asset